Cardiac hypertrophy and antihypertensive therapy

S Sen, RC Tarazi, FM Bumpus - Cardiovascular research, 1977 - academic.oup.com
S Sen, RC Tarazi, FM Bumpus
Cardiovascular research, 1977academic.oup.com
Biochemical (myocardial DNA, RNA, and hydroxyproline) and humoral (plasma [PRA] and
kidney [KRA] renin activity) factors were determined in spontaneously hypertensive rats
(SHR) and normotensive Wistar controls (NR) before and following treatment with minoxidil
or propranolol. Minoxidil (150 mg· litre− 1 drinking water) effectively controlled blood
pressure (17.3 kPa vs 24.9 kPa [130 mmHg vs 187 mmHg], P< 0.001) despite marked and
sustained increases in both PRA and KRA ventricular weight which were not reduced and …
Summary
Biochemical (myocardial DNA, RNA, and hydroxyproline) and humoral (plasma [PRA] and kidney [KRA] renin activity) factors were determined in spontaneously hypertensive rats (SHR) and normotensive Wistar controls (NR) before and following treatment with minoxidil or propranolol. Minoxidil (150 mg·litre−1 drinking water) effectively controlled blood pressure (17.3 kPa vs 24.9 kPa [130 mmHg vs 187 mmHg], P <0.001) despite marked and sustained increases in both PRA and KRA ventricular weight which were not reduced and myocardial DNA, RNA, and hydroxyproline which were increased by minoxidil (P<0.01). In contrast propranolol did not reduce blood pressure in SHR but ventricular weight was reduced somewhat (3.1 ±0.4 mg·g−1vs 3.4 ± 0.09 mg·g−1, P < 0.05); in both S HR and NR, KRA, and PRA were lowered by pranolol. Methyldopa which controlled blood pressure and lowered PRA led to a reversal of hypertrophy. Thus, although blood pressure control is obviously important for reversing cardiac hypertrophy, it may not be the sole factor for the development and reversal of cardiac hypertrophy.
Oxford University Press